# of Displayed Technologies: 10 / 13

Applied Category Filter (Click To Remove): Drug Delivery


Categories

Composition and method of lipid nanoparticles carrying oligonucleotides
TS-043629 — Novel lipid nanoparticles used for carrying antisense oligonucleotides with improved targeting for cancer treatment
Lung cancer is the leading cause of cancer related deaths in the US with approximately 150,000 deaths in 2017. Currently, mildly ineffective chemotherapeutics ripe with adverse side effects are the standard treatment. Antisense oligonucleotides (ASOs) are able to selectively modulate expression of…
  • College: College of Pharmacy
  • Inventors: Lee, Robert; Cheng, Xinwei "Evan"
  • Licensing Officer: Flammang, Ann Marie

Cold responsive nanoparticles for overcoming cancer drug resistance
TS-043509 — A cold-responsive nanoparticle that quickly disassembles upon ice cooling leading to intracellular burst release of a chemotherapeutic drug in seconds
Stimuli-responsive nanoparticles (NPs) hold great promise for controlling drug release inside cancer cells. An obstacle to the effectiveness of this approach to chemotherapeutic drug delivery is the rapid expulsion of the delivered drug catalyzed by efflux pumps in the cell's plasma membrane. …
  • College: College of Engineering (COE)
  • Inventors: He, Xiaoming; Wang, Hai
  • Licensing Officer: Norris, Francis "Frank"

Multi-Functional Cancer Drug Delivery Nanodevice for Precision Medicine
TS-041485 — Using the scaffolded DNA origami molecular self-assembly process, a manufactured DNA nanostructure can be created that circumvents MDR1/MRP-1 protein efflux pump-mediated multi-drug resistance in cancer cells to deliver clinically significant concentrations of chemotherapeutics.
The majority of human cancers remain incurable, in many cases this is due to innate or developed multi-drug resistance (MDR). Current therapeutics used in treatment are inadequate in light of such resistance, and more robust approaches must be found to circumvent these responses and deliver therap…
  • College: College of Engineering (COE)
  • Inventors: Castro, Carlos; Byrd, John; Halley, Patrick; Lucas, Christopher
  • Licensing Officer: Paschall, Christopher

Method to improve efficiency and specificity of human tumor targeting and elimination by using a combination of split & splice protein toxins and oncolytic viruses
TS-040838 — Novel strategy to improve efficiency and specificity of tumor treatment via combinative use of a split & splice protein toxin and oncolytic virus.
In combating malignancies as complex as cancer, researchers and clinicians have created a diverse set of strategies to reduce tumor burden. Oncolytic viruses (OVs) have emerged as a promising means of treating this disease due to their potential to selectively target and effectively kill cancer ce…
  • College: College of Arts & Sciences
  • Inventors: Kudryashov, Dmitri; Kudryashova, Elena
  • Licensing Officer: Flammang, Ann Marie

Multifunctional RNA Nanoparticles and Methods for Treating Cancer
TS-040289 — Three-way junction nanoparticles for delivery of tamoxifen and other therapeutics directly to tumor cells.
Most breast cancers express estrogen receptor alpha (ER α) and antagonists of ER α drugs, such as tamoxifen, have been widely used for their treatment. Unfortunately, up to half of all ER α -positive tumors have intrinsic or acquired endocrine therapy resistance. Recent studies b…
  • College: College of Pharmacy
  • Inventors: Zhang, Xiaoting; Guo, Peixuan
  • Licensing Officer: Flammang, Ann Marie

Novel compositions of nanoparticles for nucleic acid therapeutic delivery
TS-040254 — Novel lipid-based nanoparticles that utilize a surfactant to improve self-assembly and stability. Finalized particles can be used for delivery of nucleic acids such as oligonucleotides and plasmid DNA.
Lipid-based nanoparticles (LNPs) have been extensively utilized in nucleic acid delivery. However, there are a number of challenges associated with LNP formulation. It is difficult to make sub-100-nm LNPs with a high nucleic acid concentration by traditional self-assembly methods. LNP synthesis ty…
  • College: College of Pharmacy
  • Inventors: Lee, Robert
  • Licensing Officer: Flammang, Ann Marie

Sustained Release Microparticles for the Treatment of Ocular Diseases
TS-038312 — A novel, intravitreal microparticle injection capable of controlled-release of protein therapies (including anti-VEGF) for tunable periods of 6-12 months after injection for the treatment of age-related macular degeneration.
Age-related macular degeneration (AMD) is the leading cause of blindness in individuals 65 and older and is the third leading cause of blindness worldwide. Wet AMD is characterized by abnormal growth of leaky blood vessels leading to damage to the macula of the retina resulting in vision loss and …
  • College: College of Engineering (COE)
  • Inventors: Jiang, Pengfei; Reilly, Katelyn
  • Licensing Officer: Flammang, Ann Marie

Immobilization of Biomolecules (Rubisco) by Self-Assembled Nanostructures
TS-037787 — Nanostructures that enhance the stability of biocatalysts that permit them to be utilized in scalable CO2 conversion processes
Carbon dioxide (CO2) and methane (CH4) are the two most abundant greenhouse gasses, trapping thermal radiation close to the earth's atmosphere and contributing to climate change. These two gasses contributed up to 92% of all the greenhouse gas emissions in 2015 (epa.gov). From an industrial pe…
  • College: College of Arts & Sciences
  • Inventors: Parquette, Jonathan; Satagopan, Sriram; Sun, Yuan; Tabita, Fred
  • Licensing Officer: Flammang, Ann Marie

Trimodal Chemoprevention via Controlled Release Polymeric Implants
TS-037740 — Biodegradable polymeric implants for local delivery of therapeutic agents to cancer sites as an alternative to traditional radiation or chemotherapy treatments.
While surgery remains the gold standard of primary treatment for solid tumors, such as oral squamous cell carcinoma (OSCC), adjunct therapies (i.e. radiation or chemotherapy) are commonly used for patients with advanced stage or non-resectable/recurrent cancers. However, both radiation and traditi…
  • College: College of Dentistry
  • Inventors: Mallery, Susan; Schwendeman, Steven
  • Licensing Officer: Paschall, Christopher

Antisense Morpholino Treatment to Increase SMN Levels and Treat Spinal Muscular Atrophy
TS-037648 — A treatment for spinal muscular atrophy.
Spinal Muscular Atrophy (SMA) is caused by deletion or mutation of SMN1 and retention of SMN2, this in turn leads to reduced levels of the full SMN protein. SMA is the second leading cause of neuromuscular disease, and many people living with SMA need round-the-clock care from their families and a…
  • College: College of Medicine (COM)
  • Inventors: Burghes, Arthur; Porensky, Paul
  • Licensing Officer: Flammang, Ann Marie

Show More Technologies

PDF

Loading icon